CDT Equity Names Co-Founder James Bligh as CEO

A leadership transition at CDT Equity Inc. signals a consolidation phase for the Nasdaq-listed biopharmaceutical development company, with co-founder James Bligh stepping into the Chief Executive Officer role as the firm repositions its asset portfolio and balance sheet structure.

Bligh co-founded Conduit Pharmaceuticals Limited in 2019, the predecessor entity to CDT, and brings more than a decade of capital markets experience spanning reverse takeovers, IPOs, secondary fundraisings, and M&A advisory work. His appointment follows a period of structural activity at CDT that included loan note restructuring, reduction of the operating cost base, and a 22% strategic stake acquisition in Sarborg Limited, a quantum signature intelligence business.

Concurrent with Bligh's elevation, Dr. Andrew Regan has been appointed Chief Executive Officer of Sarborg. Regan's move to lead Sarborg full-time reflects the pace of development around the company's SarborgQ platform, which applies quantum computing to signature intelligence. CDT's stake in Sarborg represents one of the company's primary strategic investments under its current portfolio-building approach.

For regulatory and operational leads tracking CDT's pipeline, the leadership change arrives as the company continues to describe itself as a platform leveraging artificial intelligence, solid-form chemistry, and asset repositioning to advance therapeutic candidates. CDT has not disclosed specific pipeline milestones or regulatory submission timelines in connection with this announcement, and no clinical or GMP-related operational changes have been indicated at this stage.

The dual appointment clarifies the governance structure between CDT and its Sarborg investment, separating executive accountability across the two entities as Sarborg scales its proprietary intellectual property portfolio.

Bligh's stated strategic direction centers on science-driven and data-backed asset identification, a posture that will be tested against CDT's next disclosed pipeline or partnering milestone.

Source: GlobeNewswire via CDT Equity Inc. press release, September 1, 2026.